1. Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis 
D.W. Reid, R. Latham, I.L. Lamont, M. Camara, L.F. Roddam 
Journal of Cystic Fibrosis 
Volume 12, Issue 6, Pages (December 2013)
DOI: /j.jcf
Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

2. Fig. 1
Examples of the three different patterns of change in P. aeruginosa numbers observed with antibiotic treatment; (a) subject 6 experienced a rapid reduction in P. aeruginosa numbers (shaded columns) and sputum purulence (clear columns) by day 3, which was maintained until the end of treatment; (b) subject 7 did not experience any reduction in P. aeruginosa load or sputum purulence (purulence scores not illustrated) with antibiotic treatment during three consecutive exacerbation episodes; (c) subject 1 experienced a reduction in P. aeruginosa load by day 3, but numbers had increased almost back to baseline values by day 8. Subject 7 did not have a pre-exacerbation sample available. Sputum purulence was not scored for subject 1.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

3. Fig. 2
The correlation between sputum purulence and quantitative load of P. aeruginosa in 10 patients followed through a total of 12 exacerbations.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

4. Fig. 3
The correlation between; (a) P. aeruginosa numbers and lung function when stable pre-exacerbation; (b) reduced P. aeruginosa numbers (expressed as a proportion of the numbers present at the onset of PE) and improvements in lung function with intravenous antibiotics and; (c) the proportion of persisting P. aeruginosa and absolute FEV1 at the end of intravenous antibiotic treatment. Only those data from patients who provided sputum samples over more than seven days of treatment are presented.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions